It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?
Molecular Plant Pathology · 2025-03 · 26 (3)
DOI: 10.1111/mpp.70077 ↗At a glance
Übersichtsarbeit in Molecular Plant Pathology, published online on 2025-03-19. Written by Peter Balint-Kurti and 1 co-authors. Institution: Plant Science Research Unit, USDA-ARS, Raleigh, NC, USA. Major MEDLINE topics: Disease Resistance, Plants, Genetically Modified, Crops, Agricultural, Plant Diseases. Cited 4 times so far (Crossref); 110 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Science Foundation, National Science Foundation of Sri Lanka.
Abstract (original language)
It is more than 40 years since the era of transgenic plants began and more than 30 years after the cloning of the first plant disease resistance genes. Despite extensive progress in our mechanistic understanding and despite considerable sustained efforts in the commercial, nonprofit, academic and governmental sectors, the prospect of commercially viable plant varieties carrying disease resistance traits endowed by biotechnological approaches remains elusive. The cost of complying with the regulations governing the release of transgenic plants is often cited as the main reason for this lack of success. While this is undeniably a substantial hurdle, other transgenic traits have been successfully commercialised. We argue that a significant portion of the challenges of producing crop varieties engineered for disease resistance is intrinsic to the trait itself. In this review, we briefly discuss the main approaches used to engineer plant disease resistance. We further discuss possible reasons why they have not been successful in a commercial context and, finally, we try to derive some lessons to apply to future efforts.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Plant Science Research Unit, USDA-ARS, Raleigh, NC, USA.
- Department of Entomology and Plant Pathology, North Carolina State University, Raleigh, NC, USA.
- Seeds Research, Syngenta Crop Protection, LLC Research Triangle Park, Durnham, NC, USA.
Funding
- National Science Foundation
- National Science Foundation of Sri Lanka
Cite
APA
Balint-Kurti, P., & Liu, Q. (2025). It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?. Molecular Plant Pathology, 26(3). https://doi.org/10.1111/mpp.70077
Vancouver
Balint-Kurti P, Liu Q. It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?. Molecular Plant Pathology. 2025;26(3). doi:10.1111/mpp.70077
BibTeX
@article{BalintKurti2025,
author = {Balint-Kurti, Peter and Liu, Qingli},
title = {It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?},
journal = {Molecular Plant Pathology},
year = {2025},
volume = {26},
number = {3},
doi = {10.1111/mpp.70077}
}
EUVIMED